Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05453565
Other study ID # FRESHLY V1
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 2024
Est. completion date November 2025

Study information

Verified date October 2023
Source Australian and New Zealand Intensive Care Research Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.


Description:

This study is a prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock. The investigators will include four multicentre, open-label, randomised, clinical trials: - Australasian Resuscitation in Sepsis Evaluation Fluids of Vasopressors in Emergency Department Sepsis (ARISE FLUIDS) trial conducted in Australia and New Zealand. ClinicalTrials.gov identifier NCT04569942 - Conservative versus Liberal Approach to fluid therapy of Septic Shock in intensive Care (CLASSIC) trial conducted in seven European countries. ClinicalTrials.gov identifier NCT03668236 - Crystalloid Liberal or Vasopressors Early (CLOVERS) trial conducted in the United States. ClinicalTrials.gov identifier NCT03434028 - Early Vasopressors in Sepsis (EVIS) trial conducted in the United Kingdom. ClinicalTrials.gov identifier NCT05179499 All four trials have all received relevant approval from a research ethics committee with a locally appropriate method of obtaining consent. These trials are prospectively chosen prior to the results of any individual trial being known because they are investigating the same broad question in patients with acute septic shock across several countries. The investigators of these trials collaborated to harmonise data and outcomes as far as possible across all trials to facilitate an IPDMA. The aims to provide high level evidence to address the question of whether a fluid sparing/early vasopressor approach or a liberal fluid/later vasopressor approach to initial haemodynamic resuscitation in septic shock results in improved outcomes, including mortality.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 7838
Est. completion date November 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Participants of the ARISE FLUIDS, CLASSIC, CLOVERS & EVIS trials who had: - Suspected or proven infection - Systolic blood pressure (SBP) <100 mm Hg OR mean arterial pressure (MAP) <65 mm Hg - Lactate = 2.0 mmol/L - Requirement for vasopressors to meet perfusion targets Exclusion criteria: Participants not in the ARISE FLUIDS, CLASSIC, CLOVERS & EVIS trials

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vasopressors
A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
Fluids
A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Australian and New Zealand Intensive Care Research Centre

Outcome

Type Measure Description Time frame Safety issue
Primary All-cause mortality at 90 days post randomisation Death from any cause at 90 days after randomisation 90 days
Secondary Time from randomisation to death Time from randomisation to death Up to day 90
Secondary Incidence of mechanical ventilation Commencement of mechanical ventilation from randomisation until day 90 post-randomisation from randomisation until day 90 post-randomisation
Secondary Incidence of acute renal replacement therapy Commencement of renal replacement therapy from randomisation until day 90 post-randomisation from randomisation until day 90 post-randomisation
Secondary Days alive free of organ support at 28 days post randomisation days the patient is alive and receiving nil organ support from from randomisation until day 28 post-randomisation from randomisation until day 28 post-randomisation
Secondary Duration of hospital stay Length of time in hospital from randomisation until death or hospital discharge or day 90 post-randomisation From randomisation until day 90 post-randomisation
Secondary Incidence of serious adverse events Number of adverse events from randomisation until day 90 post-randomisation from randomisation until day 90 post-randomisation
Secondary Duration of intensive care unit (ICU) stay Length of time in ICU from randomisation until death or hospital discharge or day 90 post-randomisation From randomisation until day 90 post-randomisation
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2
Completed NCT02306928 - PK Analysis of Piperacillin in Septic Shock Patients N/A